⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11792338 | 0.78 | — | — | |
| SCHEMBL3393957 | 0.76 | CYP2D6 (0.31) | — | |
| SCHEMBL3122875 | 0.73 | CYP2D6 (0.41) | — | |
| SCHEMBL115120 | 0.73 | — | — | |
| SCHEMBL230887 | 0.73 | — | — | |
| SCHEMBL27608656 | 0.71 | EGLN1 (0.46) | — | |
| Ammonia Solution, Strong SCHEMBL3170528 | 0.71 | — | — | |
| SCHEMBL6362593 | 0.71 | — | — | |
| SCHEMBL17821044 | 0.71 | — | — | |
| SCHEMBL10758995 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987556-B2 | Dual-functional compounds and methods of use | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-05-21 | — | — | US | disclosed |
| US-11679162-B2 | Anti-5T4 antibody-drug conjugate and use thereof | HANGZHOU ADCORIS BIOPHARMA CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-20210323930-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | KINKI UNIVERSITY (JP) | 2021-10-21 | — | — | US | disclosed |
| US-20210214374-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2021-07-15 | — | — | US | disclosed |
| WO-2020069353-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-3599249-A1 | ANTI-5T4 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Zhejiang Zova Biotherapeutics Inc. (CN) | 2020-01-29 | — | — | EP | disclosed |
| EP-3572403-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2019-11-27 | — | — | EP | disclosed |
| WO-2018069851-A2 | C-MET ANTIBODY DRUG CONJUGATE | SORRENTO THERAPEUTICS, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-9216173-B2 | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150328109-A1 | DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS | MEDPHARM LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| EP-2916811-A1 | DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS | MedPharm Limited (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-20140243336-A1 | 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| EP-2763976-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-08-13 | — | — | EP | disclosed |
| WO-2014072747-A1 | DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS | MEDPHARM LIMITED (GB) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013052394-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20090143366-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1812112-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044753-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |